DGX
T2Quest Diagnostics Incorporated
Data Owners '25: Healthcare, Claims & Clinical DataMedTech Long '24: Lab Research & TrialsMedTech Long '26: Diagnostics & Early Detection
OverviewQuest Diagnostics offers global diagnostic testing, information, and related services, spanning routine to advanced clinical and anatomic pathology. It serves p
Quest Diagnostics offers global diagnostic testing, information, and related services, spanning routine to advanced clinical and anatomic pathology. It serves patients, clinicians, hospitals (like Corewell Health), and health plans, with strong growth in consumer health and innovative diagnostics such as Alzheimer's and oncology tests. The company leverages AI and automation for efficiency and patient insights.
- What They Do (Plain English & Analogies)
- Quest Diagnostics is like a giant medical detective agency for your body. When you visit the doctor and they need to understand what's happening inside, they often send samples like blood or urine to a lab for testing. Quest Diagnostics is one of the largest companies that performs these tests. They offer a wide range of diagnostic services, from common checks like cholesterol levels to highly specialized tests for complex diseases such as Alzheimer's or various cancers. Beyond just running tests, they also help doctors and hospitals manage their own labs, provide services directly to individuals who want to take charge of their health, and offer risk assessment services for the life insurance industry. Their goal is to connect people and healthcare providers with innovative testing and actionable insights to make health more proactive, personal, and connected. They are increasingly using advanced technologies like AI to make testing simpler and smarter for everyone, including patients, by translating complex lab results into easy-to-understand language.
- Very Brief History
- Quest Diagnostics Incorporated was founded in 1967 as Metropolitan Pathology Laboratory, Inc. in New York City. Over the years, it underwent several name changes and acquisitions, eventually becoming an independent company as a spin-off from Corning in 1996. Headquartered in Secaucus, New Jersey, Quest Diagnostics has grown to become a premier provider of diagnostic testing and information services, significantly expanding its offerings and reach over the decades.
- "Street Stereotype"
- Quest Diagnostics is generally perceived by investors and analysts as a stable, large-cap player in the diagnostics and early detection space. It's often seen as a crucial infrastructure provider for healthcare, especially for deploying advanced blood-based tests for conditions like Alzheimer's. The 'street' views it as a company benefiting from technological advancements in genomics and AI, and increasing demand for proactive health monitoring, despite facing ongoing reimbursement pressures and competition.
- Subsidiaries On Linked In*
- AmeriPath — Provides diagnostic solutions, advanced technology, and pathology testing.; LinkedIn: ameripath
- Dermpath Diagnostics — Focuses on accurate, clear, and prompt diagnoses of skin conditions.; LinkedIn: dermpath-diagnostics
- ExamOne — Offers risk assessment services for the life insurance industry.; LinkedIn: examone
- Quanum — Provides healthcare information technology solutions, including Lab Services Manager, eLabs, EHR, and ePrescribing.
- Quest Cardiometabolic Center of Excellence at Cleveland HeartLab — National center of excellence focused on identifying hidden heart disease risk.
- ReproSource — Focuses exclusively on reproductive health testing.
- Blueprint Genetics — Provides high-quality genetic testing across 15 medical specialties.; LinkedIn: blueprint-genetics
- Athena Diagnostics — Runs highly comprehensive diagnostic testing for neurological, endocrine, and renal conditions.
- Labtech Diagnostics — Provides reliable, timely, accurate, and innovative diagnostic services.
- Customer Sectors & Example Clients
- Quest Diagnostics serves a broad range of customer sectors including patients, clinicians (physicians), hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Specific top clients and collaborators mentioned include Fresenius Medical Care (for comprehensive kidney testing and dialysis-related lab services), Corewell Health (a leading health system in Michigan, for collaborative lab solutions and a joint venture), and City of Hope (a cancer and research treatment organization, for a research collaboration on the Haystack MRD test). They also partner with top consumer health brands, wearable companies, and functional and wellness companies.
- New Customers / Segments They'Re Targeting
- Quest Diagnostics is actively targeting new customer segments and expanding into new clinical areas. This includes end-stage renal disease, where they are focused on lab testing for dialysis patients, serving thousands of dialysis clinics operated by Fresenius Medical Care nationwide, and adding independent dialysis clinics and other providers as clients. They are also expanding their collaborative lab solutions (Co-Lab) with health systems, aiming to free up hospital capital while providing expertise and innovation. In the consumer channel, they are targeting individuals who want to own their health through questhealth.com and partnerships with top consumer health brands and wearable companies. Furthermore, they are driving advanced diagnostics in five key clinical areas: advanced cardiometabolic and endocrine, autoimmune, brain health, oncology, and women's and reproductive health.
- Supply Chain And Sourcing Geographies
- Quest Diagnostics' supply chain is extensive, encompassing both clinical and operational needs, and represents approximately $3.7 billion in global economic activity. For clinical aspects, they procure laboratory reagents and consumables, specimen collection kits, diagnostic equipment, medical devices, and laboratory information system software. These are primarily sourced from large, well-known, FDA-regulated suppliers in life sciences and in vitro diagnostics (IVD) manufacturing, many of whom have a significant U.S. presence and global manufacturing footprints. Operationally, they source facilities management, janitorial services, construction, security, fleet services, logistics, and professional services. The company leverages a national procurement network and significant purchasing power in the United States. While specific geographic sourcing for all components beyond the U.S. is not detailed, the global nature of their suppliers and operations in countries like India, Ireland, and Mexico suggests a diverse international sourcing network.
- Sales Geographies And Expansion Plans
- Quest Diagnostics primarily operates in the United States, serving one in three adult Americans and half the physicians and hospitals, with a national network of laboratories and approximately 2,000 patient service centers. Internationally, Quest Diagnostics has operations in India, Ireland, and Mexico, and its products and services are used by customers in over 130 countries and on six continents. Their Nichols Institute Worldwide performs specialized testing for clients in more than 50 countries across North America, South America, Europe, Asia, and Australia. The company is actively expanding its sales and reach through several initiatives: the New York State approval for its Haystack MRD test allows commercial efforts in all 50 U.S. states; they are forming new Co-Lab agreements with health systems, such as the joint venture with Corewell Health in Michigan, with plans to open a state-of-the-art lab in Southeast Michigan next year; and they continue to grow their consumer health partnerships globally.
- How Key Themes May Help/Hurt
- The "MedTech Long '26: Diagnostics & Early Detection" theme is largely beneficial for Quest Diagnostics. Accelerating technological advancements in genomics, AI, and multiomics directly drive the development and adoption of highly effective diagnostic and early detection technologies, expanding clinical utility and market opportunities for Quest's advanced diagnostics like AD-Detect and Haystack MRD. The increasing global prevalence of chronic diseases and an aging population create a sustained demand for advanced diagnostic solutions and proactive health monitoring, fueling the need for Quest's early detection tests. Favorable regulatory developments and legislative actions, such as the potential passage of the MCED Act, could enhance market access and accelerate commercialization for multi-cancer early detection tests, which Quest is involved in through its Haystack MRD test. Quest's significant investments in AI and automation across its operations, including the Quest AI Companion, align perfectly with the theme's emphasis on AI-powered platforms and improved efficiency. Conversely, persistent reimbursement pressures and evolving payer policies, particularly regarding PAMA data collection and potential average selling price (ASP) declines, could impact profitability and market uptake for Quest's tests. Significant regulatory hurdles and the requirement for extensive evidence generation for novel tests can impede timely rollout and broad adoption, as seen with ongoing challenges in the MCED field. Intensifying competition from both established players and new entrants in the diagnostics and early detection space may lead to pricing pressures, increased commercialization costs, and potential margin compression for Quest, particularly in high-growth segments like liquid biopsy.
3 Main Long-Term Bull Details
- Leadership in Advanced Diagnostics and Innovation: Quest Diagnostics is driving significant growth through its innovative advanced diagnostic solutions, particularly in high-growth areas like brain health (e.g., AD-Detect blood test for Alzheimer's, which more than doubled year-over-year in Q1 2026) and oncology (e.g., Haystack MRD test, with a research collaboration with City of Hope). New American Heart Association guidelines recommending Lp(a) and ApoB testing further expand the eligible patient population. Continuous investment in R&D and collaborations with therapy makers position them at the forefront of early disease detection and management.
- Operational Excellence and AI/Automation Integration: The company's focus on operational excellence through its Invigorate program aims for 3% annual cost savings and productivity improvements. Significant deployment of AI and automation, both in labs and customer service (e.g., a 40% boost in customer service agent productivity through AI in Q1 2026), enhances efficiency, quality, and patient experience. The new Quest AI Companion, powered by Google Gemini, saw approximately 350,000 patient engagements in Q1, empowering health ownership.
- Strategic Collaborations and Consumer Health Expansion: Quest is successfully expanding its market reach and revenue through strategic collaborations with elite healthcare organizations (e.g., Corewell Health Co-Lab joint venture, Fresenius Medical Care for kidney care). Its direct-to-consumer platform, questhealth.com, and partnerships with consumer health organizations continue to generate robust double-digit revenue growth, diversifying revenue streams and strengthening market presence.
3 Main Long-Term Bear Details
- Reimbursement Pressures and Regulatory Uncertainty (PAMA): Persistent reimbursement pressures and evolving payer policies, particularly from government programs like Medicare (PAMA), pose a significant risk. The uncertainty around 2027 Medicare rates, the potential for skewed data submissions, and the anticipated 30 basis point revenue impact from the expiration of ACA exchange subsidies could negatively impact profitability.
- Execution Risks with Large-Scale Transformation Projects and Macroeconomic Headwinds: Large-scale transformation initiatives like Project Nova, while aiming for long-term benefits, involve significant upfront expenses, with over 60% of the anticipated $0.25 EPS dilution expected in the second half of 2026. Additionally, macroeconomic factors such as higher fuel costs (projected to be $7 million to $10 million annually) and wage increases can put pressure on operating margins, partially offsetting productivity gains.
- Intensifying Competition and Pricing Pressures: The diagnostics market remains highly competitive, with pricing pressures evident in some segments, particularly the hospital reference business. The business mix from new collaborations like Fresenius Medical Care and Corewell Health, which include a greater proportion of routine tests, led to a 1.3% decrease in total revenue per requisition in Q1 2026, indicating potential margin dilution from certain high-volume partnerships.
- Competitors And Differentiation
- Quest Diagnostics operates in a competitive diagnostics market. While specific competitors are not explicitly named in the provided transcript for DGX, the existing text tables mention LabCorp and Thermo Fisher Scientific as established players. The transcript alludes to competition in the PAMA data submission process, noting that historically only two companies (including Quest and its nearest competitor) submitted the majority of data. Quest differentiates itself through its scale, clinical depth, and operational excellence, which it leverages in its collaborative lab solutions for hospitals. The company also emphasizes its innovative solutions, such as the AD-Detect blood test for Alzheimer's and the Haystack MRD test for oncology, and its commitment to consumer health through questhealth.com and partnerships. Quest also highlights its use of automation and AI to improve productivity and quality, and to enhance the patient experience, such as with the Quest AI Companion. They advocate for fair reimbursement practices, noting that some health plans pay health system labs 200% to 300% more than leading independent labs for outreach work, which they believe penalizes patients and employers.
- Recent Performance & What The Market'S Focused On
- Quest Diagnostics had a strong start to 2026, reporting robust first-quarter performance with consolidated revenues up 9.2% year-over-year and adjusted diluted EPS growing by approximately 13%. This strong momentum led the company to raise its revenue and EPS guidance for the full year. The market is focused on the sustainability of this organic volume growth, particularly the contributions from key partnerships like Fresenius Medical Care and Corewell Health, which accounted for about 7% of organic volume growth in Q1. Analysts are also closely watching the impact of PAMA data collection on 2027 Medicare rates and the progress of the RESULTS Act, as well as the execution of Project Nova and its associated expenses. The growth in advanced diagnostics, consumer health, and the benefits from AI and automation are also key areas of market attention.
- Revenue Segments And Estimated Mix
- Consolidated Revenues — Mix: 100%; Source: Q1 2026 earnings call; Trend: Up 9.2% YoY; 9% organic revenue growth. Full year 2026 guidance: $11.78B-$11.9B (6.8%-7.8% growth).
- Diagnostic Information Services — Mix: Largest segment, majority of consolidated revenues; Source: Q1 2026 earnings call; Trend: Up 9.4% YoY.
- Physician Channel — Mix: Significant portion of Diagnostic Information Services; Source: Q1 2026 earnings call; Trend: High single-digit revenue growth.
- Hospital Channel — Mix: Significant portion of Diagnostic Information Services; Source: Q1 2026 earnings call; Trend: Double-digit revenue growth, majority from Corewell Health.
- Consumer Channel (questhealth.com and partnerships) — Mix: Growing rapidly; Source: Q1 2026 earnings call; Trend: Significant revenue growth; questhealth.com with robust double-digit customer repeat rates, partnerships even stronger double-digit growth.
- Advanced Diagnostics (across 5 key clinical areas) — Mix: Growing portion of testing volume; Source: Q1 2026 earnings call; Trend: Double-digit revenue growth across several areas (e.g., brain health, cardiometabolic and endocrine). AD-Detect blood test more than doubled YoY.
- Product Brands
- questhealth.com
- AD-Detect
- Haystack MRD
- MyQuest app
- Quest AI Companion
- Elite health profile
- Lp(a) test
- ApoB test
- IntelliDraw
- Hologic Genius digital diagnostic system
Bull / Bear DetailsQuest Diagnostics maintains a bullish outlook as of 2026-07-26, driven by robust Q1 2026 organic revenue and adjusted EPS growth, leading to raised full-year gu
Thesis
Quest Diagnostics maintains a bullish outlook as of 2026-07-26, driven by robust Q1 2026 organic revenue and adjusted EPS growth, leading to raised full-year guidance. Strong performance across physician, hospital, and consumer channels, coupled with significant advancements in innovative diagnostics like AD-Detect and Haystack MRD, reinforces its market leadership. Strategic collaborations and expanding AI-driven operational efficiencies further enhance its resilient growth trajectory, despite ongoing reimbursement pressures and execution risks.
Bull case
Quest Diagnostics is driving significant growth through innovative advanced diagnostic solutions, with the AD-Detect blood test for Alzheimer's disease more than doubling year-over-year in Q1 2026. New American Heart Association guidelines recommending Lp(a) and ApoB testing further expand the eligible patient population, while a research collaboration with City of Hope for the Haystack MRD test in solid tumors underscores continued innovation.
The company's focus on operational excellence is yielding substantial productivity gains, including a 40% boost in customer service agent productivity through AI in Q1 2026. Furthermore, the new Quest AI Companion, powered by Google Gemini, saw approximately 350,000 patient engagements in Q1, enhancing patient experience and empowering health ownership, alongside continued AI and automation deployment in labs.
Quest is successfully expanding its market reach and revenue through strategic collaborations, with Fresenius Medical Care and Corewell Health contributing approximately 7% to organic volume growth in Q1 2026. Its direct-to-consumer platform, questhealth.com, and partnerships with consumer health organizations continue to generate robust double-digit revenue growth, diversifying revenue streams and strengthening market presence.
Bear case
Persistent reimbursement pressures and regulatory uncertainty, particularly regarding PAMA data collection and the uncertain outcome for 2027 Medicare rates, pose a significant risk. Despite efforts to advance the RESULTS Act, its passage faces challenges due to upcoming summer vacations and elections. The company also anticipates a 30 basis point revenue impact from ACA exchange subsidy expiration for the full year.
Execution risks with large-scale transformation initiatives like Project Nova involve significant upfront expenses, with over 60% of the anticipated $0.25 EPS dilution expected in the second half of 2026. Operating margins are also impacted by elevated fuel costs, projected to be $7 million to $10 million annually, and the expectation of some negative weather impact in the second half of the year.
The diagnostics market remains highly competitive, with pricing pressures evident in some segments, particularly the hospital reference business. Additionally, the business mix from new collaborations like Fresenius Medical Care and Corewell Health, which include a greater proportion of routine tests, led to a 1.3% decrease in total revenue per requisition in Q1 2026.
Bull / Bear Case
- Bear Case
- Quest Diagnostics faces persistent reimbursement pressures and regulatory uncertainty, particularly concerning PAMA data collection and the unpredictable outcome for 2027 Medicare rates, with the RESULTS Act's passage challenged by upcoming legislative breaks and elections. The company also anticipates a 30 basis point revenue impact from ACA exchange subsidy expiration. Execution risks are present with large-scale transformation initiatives like Project Nova, which is expected to incur over 60% of its $0.25 EPS dilution in the second half of 2026. Operating margins are further pressured by elevated fuel costs, projected at $7 million to $10 million annually, and anticipated negative weather impacts. Additionally, the business mix from new collaborations, comprising a higher proportion of routine tests, led to a 1.3% decrease in total revenue per requisition in Q1 2026, highlighting competitive and pricing pressures in certain segments.
- Bull Case
- Quest Diagnostics demonstrates strong momentum with robust Q1 2026 organic revenue growth of 9% and adjusted EPS growth of 13%, leading to raised full-year guidance. This performance is fueled by significant advancements in innovative diagnostics, such as the AD-Detect blood test for Alzheimer's disease, which more than doubled year-over-year, and new guidelines expanding testing for cardiometabolic health. Operational excellence initiatives, including the Invigorate program, are yielding substantial productivity gains through AI and automation, boosting customer service efficiency by 40% and enhancing patient engagement via the Quest AI Companion. Strategic collaborations with major healthcare systems like Corewell Health and Fresenius Medical Care, alongside robust double-digit growth in the direct-to-consumer platform questhealth.com, are successfully expanding market reach and diversifying revenue streams.
- More Compelling & Why
- Bull. Given DGX's strong Q1 performance and raised full-year guidance, the market has reacted positively, with the stock outperforming the SPY post-earnings. The forward P/E of approximately 16x (hypothetical) appears reasonable for a company demonstrating consistent organic growth in advanced diagnostics and leveraging AI for efficiency. The strongest argument is the sustained organic revenue and adjusted EPS growth, driven by innovative solutions and strategic collaborations. A significant, unexpected negative outcome from PAMA, leading to substantial Medicare rate cuts, would flip my view to bear.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Corewell Health Co-Lab to JV Transition Progress | The successful transition of the Corewell Health Co-Lab into a Joint Venture (JV) is a significant strategic milestone, indicating deeper collaboration and long-term revenue contribution from a key hospital partnership. | Updates on the scaling up of the Corewell Co-Lab and specific timelines or milestones for the JV launch in early 2027. | Continued positive commentary on scaling and clear progress towards early 2027 JV launch = bullish signal. Any delays or challenges in the transition = bearish signal. | Quest Diagnostics earnings calls and press releases. Next earnings call (Q3 2026) would be the earliest for further updates. | Corewell Health press releases/news. Local Michigan business news. | Thinknum: Quest Diagnostics job postings in Michigan related to Corewell, indicating hiring for the JV. |
| Consolidated Organic Revenue Growth and Volume Trends (Q3 2026) | Sustained strong organic revenue growth and volume increases demonstrate robust underlying demand for Quest's diagnostic services across its channels, supporting the raised full-year guidance and overall business health. | Q3 2026 consolidated organic revenue growth rate (Q2 was 10%), total volume growth (Q2 was 13.1%), and organic volume growth (Q2 was 13%). Management noted July volumes were consistent with Q2. | Organic revenue growth > 9% and volume growth > 10% = bullish signal. Significant deceleration below these rates = bearish signal. | Quest Diagnostics Q3 2026 earnings release and conference call (expected late October 2026). | Google Trends: 'Quest Diagnostics' search volume. Industry reports on general diagnostic testing volumes. | Earnest Analytics: Diagnostic test volume data. Similarweb: Quest Diagnostics website traffic. |
| Haystack MRD MolDx Medicare Advantage Reimbursement | Securing Medicare Advantage reimbursement for Haystack MRD would significantly expand market access and revenue potential for this high-growth oncology test, validating its clinical utility and driving adoption. | Announcement of MolDx Medicare Advantage coverage for Haystack MRD. Quest Diagnostics expects this in the second half of 2026. | If MolDx Medicare Advantage reimbursement is received in H2 2026 = bullish signal. If delayed or denied = bearish signal. | Quest Diagnostics press releases, SEC filings (Form 8-K), MolDx website updates. Expected in H2 2026. | Google Trends: 'Haystack MRD reimbursement', 'MolDx coverage ctDNA'. Industry news sites (e.g., Fierce Biotech, GenomeWeb) for announcements. | Thinknum: Haystack MRD job postings (sales/medical affairs) growth, indicating commercial ramp-up. |
| PAMA Data Collection Outcome and RESULTS Act Progress | The outcome of PAMA data collection and the progress of the RESULTS Act directly impact future Medicare reimbursement rates for diagnostic tests, affecting Quest's overall revenue and profitability. | CMS report on PAMA data collection (expected late September/early August 2026). Legislative progress of the RESULTS Act (markup process, CBO scoring). | If CMS acknowledges flaws in data collection or if the RESULTS Act progresses significantly (e.g., passes House/Senate) = bullish signal (for stable/fair reimbursement). If new PAMA rates are implemented with significant cuts or RESULTS Act stalls = bearish signal. | CMS announcements, Quest Diagnostics investor relations updates, industry trade association (e.g., ACLA) press releases, Congressional legislative tracking websites. CMS report expected late Sept/early Aug 2026. | GovTrack.us: RESULTS Act legislative status. Google News: 'PAMA reimbursement', 'RESULTS Act'. CMS.gov for official announcements. | FiscalNote: Healthcare policy tracking, legislative sentiment analysis. |
| Adjusted Operating Margin Expansion (Q3 2026) | Achieving full-year adjusted operating margin expansion, despite anticipated headwinds like higher Nova expenses and fuel costs in H2, indicates effective cost management and leverage from revenue growth, crucial for profitability. | Q3 2026 adjusted operating margin percentage. Commentary on the impact of Nova expenses, fuel costs, and the dilutive effect of Corewell/Fresenius. | Q3 adjusted operating margin showing improvement or stability, and reaffirmation of full-year expansion = bullish signal. Significant margin compression or revised guidance for full-year margin = bearish signal. | Quest Diagnostics Q3 2026 earnings release and conference call (expected late October 2026). | EIA (Energy Information Administration): US gasoline prices (proxy for fuel costs). BLS (Bureau of Labor Statistics): Wage growth data (proxy for labor costs). | Thinknum: Quest Diagnostics job postings (wage inflation proxy, hiring efficiency). |
Key Reported Metrics, Reratings Triggers & ResultsConsolidated Revenues reflect the overall top-line performance and market demand for Quest Diagnostics' services. Strong growth indicates successful execution o
| Key reported metrics | ||
|---|---|---|
| Metric | Last period | Why it matters |
| Consolidated Revenues | 10.2% | Consolidated Revenues reflect the overall top-line performance and market demand for Quest Diagnostics' services. Strong growth indicates successful execution of strategy and expanding market share, which is crucial for investor confidence. |
| Revenue per Requisition (adjusted for business mix) | 2.9% | This metric indicates the underlying pricing power and mix shift towards higher-value tests, excluding the impact of new, lower-margin collaborations. Its growth suggests increased test complexity and success in advanced diagnostics and consumer health. |
| Adjusted Diluted EPS | 19.1% | Adjusted Diluted EPS is a key indicator of Quest Diagnostics' profitability and operational efficiency. Strong growth signals effective cost management, leverage from revenue growth, and ultimately, enhanced shareholder value. |
Key QuestionsWill the PAMA data submission by the end of July and the progress of the RESULTS Act lead to favorable Medicare reimbursement rates for 2027, and will Haystack
Will the PAMA data submission by the end of July and the progress of the RESULTS Act lead to favorable Medicare reimbursement rates for 2027, and will Haystack MRD secure MolDx Medicare Advantage reimbursement as expected?
- Question 2
Can Quest Diagnostics achieve its full-year operating margin expansion target given the anticipated ramp-up of Project Nova expenses (over 60% in H2) and elevated fuel costs, and will the improving margin profile from Corewell and Fresenius partnerships offset these pressures in the second half?
- Question 3
Can Quest Diagnostics sustain its strong organic revenue growth momentum, driven by continued demand for advanced diagnostics like AD-Detect and Haystack MRD, and the ongoing contributions from key collaborations such as Corewell Health and Fresenius Medical Care?
Earnings Transcript Summary
· 2026Q2 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. Strategic Execution and Growth: Management emphasized 'focused execution of our strategy to connect people and providers to innovative testing and actionable insights', highlighting broad clinical demand, new customer wins, and increased volume from collaborations like Corewell Health and Fresenius Medical Care. They are also focused on expanding advanced diagnostics in key clinical areas such as brain health, oncology (Haystack MRD), and cardiometabolic tests. 2. Operational Excellence and Technology Adoption: A key focus is on driving continuous improvements in quality and productivity through the 'Invigorate program' (aiming for 3% annual cost savings) and investing in 'automation and AI' both in and outside labs, including systems like Hologic Genius and tools like IntelliDraw. 3. Expanding Collaborations and Acquisitions: Management is actively pursuing and growing strategic partnerships, citing the success of Co-Lab Solutions with Corewell Health and Fresenius Medical Care, and a new Co-Lab agreement in California, indicating a strong pipeline for future collaborations and acquisitions of hospital outreach and independent labs. | The overall takeaway from the call is highly positive, reflecting strong financial performance in Q2 2026 with robust top and bottom-line growth, leading to a raised full-year guidance for both revenue and adjusted EPS. Management expressed confidence in their strategic execution, driven by broad clinical demand, successful collaborations, and investments in automation and AI. The tone was optimistic, emphasizing continued momentum and strategic focus, despite acknowledging ongoing reimbursement pressures from PAMA and potential increased expenses in the second half of the year. | Consolidated Revenues: Up 9.2% YoY. Consolidated Organic Revenues: Up 9% YoY. Diagnostic Information Services: Up 9.4% YoY. Physician Channel: High single-digit revenue growth. Hospital Channel: Double-digit revenue growth, majority from Corewell Health. Consumer Channel (questhealth.com and partnerships): Significant revenue growth, questhealth.com with robust double-digit repeat rates, partnerships even stronger double-digit growth. Advanced Diagnostics (across 5 key clinical areas): Double-digit revenue growth across several areas (e.g., brain health, cardiometabolic and endocrine). | 1. Hospital Channel Performance and Deal Pipeline: Analysts questioned the double-digit growth in the hospital channel, the progression of relationships, the building deal pipeline, and concerns about bad debt exposure. Management responded that the total hospital portfolio was up significantly, driven by Corewell Health. They noted mid-single-digit growth in core reference business and Co-Lab same-store sales (excluding Corewell), indicating no slowdown. They also stated that bad debt is not a concern with hospitals or client bills, and the funnel of opportunities for Co-Lab and outreach deals looks good. 2. Impact of ACA/Medicaid Changes: Analysts asked about the 30 basis points headwind from ACA and Medicaid changes and if it was still embedded in guidance. Management confirmed that the 30 basis point impact is still assumed for the full year. They explained that while enrollment is down, the impact on their business is limited because healthier people dropped off, and sicker people remained, leading to fewer requisitions but more tests per requisition, keeping revenue from the exchange relatively flat. 3. PAMA Reimbursement Outcomes and Mitigation Strategies: Analysts inquired about the potential reimbursement outcomes from PAMA and actions to offset future risks. Management outlined three possible outcomes: new rates implemented by CMS after the July 30 data collection, the passage of the RESULTS Act (which they continue to push for due to strong bipartisan support and a belief it's a fairer way to collect data), or another delay if the RESULTS Act doesn't pass, given Congress's acknowledgment of PAMA's flaws. | Consolidated revenues: up 10.2% year-over-year. Consolidated organic revenues: up 10% year-over-year. Diagnostic Information Services: up 10.3% year-over-year. Diagnostic Information Services organic growth: 10.1% year-over-year. Physician channel: high single-digit revenue growth. Hospital channel: double-digit revenue growth. Consumer health channel (questhealth.com): robust revenue growth. Advanced diagnostics (across 5 key clinical areas): double-digit revenue growth across several areas. |
· 2026Q1 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. **Delivering innovative solutions and expanding clinical areas**: Management highlighted strong demand for clinical innovations, such as the AD-Detect blood test for Alzheimer's disease (which more than doubled year-over-year) and advanced cardiometabolic testing. They also emphasized expansion into new clinical areas like end-stage renal disease and collaborative lab solutions with health systems like Corewell Health. 2. **Operational excellence and leveraging AI/automation**: The company is focused on improving productivity and quality through its Invigorate program, aiming for 3% annual cost savings. They are stepping up the deployment of AI and automation both in and outside labs, including boosting customer service productivity by 40% with AI and launching the Quest AI Companion for patients. 3. **Strategic collaborations and consumer health**: Management is actively pursuing and benefiting from collaborations with elite healthcare and consumer health organizations, driving significant revenue growth from questhealth.com and partnerships with wearable companies and wellness brands. They see this convergence of consumer health, wellness, wearables, and AI as having a profound impact on future healthcare. | The overall takeaway of the call was highly positive, reflecting a strong start to the year for Quest Diagnostics. Management reported robust first-quarter performance with significant revenue and EPS growth, driven by broad-based demand for clinical innovations, successful expansion into new clinical areas, and effective collaborations. The tone was confident and optimistic, underscored by the decision to raise full-year revenue and EPS guidance. Key themes included the successful execution of strategic initiatives, the increasing adoption of advanced diagnostics, the benefits of AI and automation in operations, and the growing momentum in the consumer health segment. | In Q4 2025, consolidated revenues were up 7.1% year-over-year. Consolidated organic revenues grew by 6.4% year-over-year. Diagnostic Information Services were up 7.3% year-over-year. The physician channel experienced high single-digit organic revenue growth. The hospital channel saw low single-digit growth. The consumer-initiated testing platform, questhealth.com, exceeded a 20% revenue growth rate. Advanced Diagnostics across several clinical areas showed double-digit revenue growth. | 1. **Organic volume dynamics and contributions from key partnerships**: Analysts questioned the drivers of strong organic volume growth, particularly the impact of Fresenius Medical Care and Corewell Health. Management responded that organic volume growth was 10.8% (10.9% total), with Fresenius and Corewell contributing about 7%, meaning 3.8% organic volume growth excluding these two. They also clarified that revenue per requisition was down 1.3% overall due to the business mix of these collaborations but up 2.5% excluding their impact, driven by an increase in tests per requisition from advanced diagnostics and consumer business. 2. **PAMA (Protecting Access to Medicare Act) and 2027 Medicare rates**: Analysts inquired about Quest's preparation for PAMA data submission and expectations for 2027 Medicare rates. Management confirmed readiness to submit data and expressed hope that if all eligible labs submit, the data would show that rates should increase, as previous submissions were skewed by only a few large providers. They also highlighted efforts to advance the RESULTS Act to keep rates as is for 2027. 3. **Impact of government fraud, waste, and abuse initiatives (CRUSH RFI) and prior authorizations**: Analysts asked about the CMS' CRUSH RFI and its potential impact. Management stated that Quest does not believe it will be impacted, as 7 of the 10 tests driving the majority of increased Medicare lab spending were proprietary tests Quest does not offer, and their participation in the other 3 molecular-based categories was de minimis. They applauded government efforts against fraud but noted that routine and wellness tests, critical for preventative health, were actually down according to the OIG report. Regarding prior authorizations, management stated they would not ask for them, but suggested CMS require accreditation for labs performing higher complexity tests. | Consolidated revenues were up 9.2% year-over-year. Consolidated organic revenues grew by 9% in the quarter. Revenues for Diagnostic Information Services were up 9.4% compared to the prior year. The physician channel delivered high single-digit revenue growth. The hospital channel grew revenues at a double-digit rate. The consumer channel generated significant revenue growth, with questhealth.com featuring robust double-digit customer repeat rates and partnerships showing even stronger double-digit growth. Advanced diagnostics across several key clinical areas (advanced cardiometabolic and endocrine, autoimmune, brain health, oncology, and women's and reproductive health) delivered double-digit revenue growth. The AD-Detect blood test for Alzheimer's disease more than doubled year-over-year. The hospital reference business was up 3%. The Co-Lab business with Corewell Health was up significantly double-digit growth. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Quest Diagnostics expanded its reach through collaborations with Corewell Health and Fresenius Medical Care, driving increased volume. The company also formed a new Co-Lab agreement with a nonprofit regional health system in California. The consumer health channel, including questhealth.com, continued robust revenue growth and attracted new partners. Growth was double-digit across several advanced diagnostic areas like cardiometabolic, autoimmune, brain health, and oncology. New York State approved the Haystack MRD test, allowing commercial efforts in all 50 states, and access was extended through Flatiron Health's Onco EMR Molecular Profiling integration platform. Elevance recently added coverage for the pTau 217 Alzheimer's biomarker, and Medicare Advantage offers broad reimbursement for Alzheimer's panels. The hospital reference business saw mid-single-digit revenue growth, indicating a willingness to outsource more tests, and the pipeline for Co-Lab and outreach deals looks good. | Regarding the Haystack MRD test, Quest Diagnostics believes its assay is 'better than some of the competitors that are out there.' In the context of PAMA, the company noted that 'only one other company' has New York State approval for a tumor-informed ctDNA MRD test. The hospital reference business is described as a 'competitive sector' with 'slightly negative' pricing. Quest Diagnostics advocates for the RESULTS Act to address flaws in the original PAMA data collection process, which resulted in a 'very, very biased statistical sample' of market pricing, suggesting a need for a 'better and fair way' to collect data. | Hospitals continue to face 'workforce, financial and other pressures.' There is a growing interest and investment in preventative health and wellness, with consumers increasingly 'taking on of their own health and taking charge of their health.' While ACA exchange enrollment is down, the 'healthier people dropped off, the sicker people remained,' leading to fewer requisitions but more tests per requisition and relatively flat revenue from exchanges. The industry is seeing sustained demand driven by 'chronic conditions that continue to exist in this country.' New treatments for late-stage liver disease are poised for additional growth in liver fibrosis testing. The International Alzheimer's conference highlighted the 'widespread perspective of the importance of both biomarkers' (pTau and amyloid beta) for dementia care. Congress has acknowledged that the original PAMA cuts were 'not sustainable' and the process 'did not work as intended.' | Quest Diagnostics is raising its full-year guidance for 2026, expecting revenues between $11.95 billion and $12.05 billion (8.3% to 9.2% growth) and adjusted EPS between $11.05 and $11.25. The company anticipates continued expansion of its consumer health platform and solutions for partners. Operational excellence initiatives, including the Invigorate program, are on track to deliver 3% in annual cost savings and productivity improvements. AI and automation investments will continue, with plans to extend front-end specimen processing automation to more sites and implement an AI tool at patient service centers this year. The Corewell Health Co-Lab is expected to scale up to a JV and launch early next year. Haystack MRD commercial investments are being paced commensurate with reimbursement, with MolDx Medicare Advantage reimbursement hoped for in the second half of the year. Utilization is expected to remain strong in the second half, though ACA subsidies will have a higher impact, and the company will lap Corewell and Fresenius in Q4. PAMA has three possible outcomes: new rates implemented January 1, 2027, the RESULTS Act passed, or another delay, with Quest continuing to push for the RESULTS Act. | Diagnostics | The deep integration of AI and automation is a broader theme emerging across the industry, impacting lab operations, customer engagement, and administrative tasks. This is evidenced by Quest's use of AI for Pap test slide scanning, front-end specimen processing, customer engagement tools like IntelliDraw, and an AI tool for tracking and ordering supplies at patient service centers. | Our strong performance in the second quarter demonstrates focused execution of our strategy. In the quarter, we grew revenues by over 10%. We also grew adjusted diluted earnings per share by over 19%. We are again raising our guidance for the year. We are seeing no slowdown at all from reference testing coming to Quest Diagnostics. Our core physician business... is getting growth in the high single digits, both volume and revenue. Our Consumer business... is on the high side of that estimate. The utilization has been very strong, and we really are expecting the same tailwind to continue in the second half. Revenue per requisition was very strong in the quarter. Test per req is definitely continuing to improve. Elevance recently added coverage for certain blood-based biomarker tests for Alzheimer's. Brain health portfolio continues to grow at high double-digit rates. | Operating income as a percent of revenues was impacted by investments in Project Nova and the lower operating margin rate associated with the ramp of the Corewell Co-Lab business. Operating income was also adversely impacted by higher supplemental deferred compensation expenses. Total revenue per requisition was down 2.8% versus the prior year due to the Corewell and Fresenius business mix. Fuel costs... for the year to be at the high end of the range that we previously gave, which is equivalent to close to about $10 million. Nova expenses in the second half to be about 70% of the full year. It's a competitive sector, and the pricing is slightly negative there. The ACA exchange subsidy expiration... still assuming for the full year that there's a 30 basis point impact on revenue. DSOs are up again both year-over-year and sequentially in the quarter. We don't want to get too far out in front of ourselves [Haystack MRD]... commensurate with reimbursement. Q3, always a wildcard [weather]. | Quest Diagnostics welcomed Domini Chokshi as the new Head of Investor Relations, who joined last week, bringing nearly two decades of experience from Merck. Dan Haemmerle, the Vice President of Finance, will assist in her transition after leading the Investor Relations function for the past few months. Wage increases were mentioned as a factor partially offsetting organic revenue growth and impacting operating income. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Quest Diagnostics is expanding into new clinical areas such as end-stage renal disease, serving thousands of dialysis clinics operated by Fresenius Medical Care nationwide and adding independent dialysis clinics. The company is also growing its collaborative lab solutions (Co-Lab) with health systems like Corewell Health, with a strong pipeline for future collaborations and acquisitions. In the consumer channel, significant revenue growth is driven by questhealth.com and partnerships with consumer health organizations, including wearable companies. Advanced diagnostics are a key focus across five clinical areas: advanced cardiometabolic and endocrine, autoimmune, brain health, oncology, and women's and reproductive health, with double-digit revenue growth in several of these. The AD-Detect blood test for Alzheimer's disease more than doubled year-over-year. New guidelines from the American Heart Association recommend Lp(a) and ApoB testing for the first time and recommend screening for high cholesterol at young ages, expanding the eligible patient population. A research collaboration with City of Hope is studying the Haystack MRD test for solid tumor cancers across 14 U.S. sites. The partnership with Guardant for the Shield colon cancer CRC test is also expanding Quest's offerings. | Quest Diagnostics notes that in the PAMA data submission process, historically, only two companies (including Quest and its nearest competitor) submitted over 80% of the data, despite having at best 17% to 20% share of the Medicare market, which could lead to inaccurate rate assessments. The company also highlights that many health plans pay health system labs 200% to 300% of what they pay leading independent labs for outreach work, which penalizes patients and employers. Quest advocates for health plans to pay all labs the same amount for outreach work. | The broader industry is seeing a significant shift towards advanced diagnostics and early detection, with physicians becoming more confident using blood tests for diagnosis and treatment decisions, often in lieu of imaging, particularly for conditions like Alzheimer's. New clinical guidelines, such as those from the American Heart Association for Lp(a) and ApoB testing and early cholesterol screening, are driving demand for specific biomarkers. There's a strong industry trend towards leveraging AI and automation for productivity gains, both within labs and in customer service operations. The government is increasing efforts to combat fraud, waste, and abuse in healthcare, as evidenced by the CMS' CRUSH RFI, which noted a 5% increase in Medicare lab spending driven by 10 specific tests (7 proprietary to individual labs, 3 molecular-based); however, routine and wellness tests, critical for preventative health, were actually down. There is an emerging convergence of consumer health, wellness, wearables, and AI, which is expected to profoundly impact how people manage their healthcare, leading to a future where pre-doctor visit data (wearable, lab work) is fed into AI for personalized reports and more informed discussions with physicians. This linkage between biomarkers and biometrics, supported by AI, is making people more conscious of their health and likely increasing longitudinal testing. | Quest Diagnostics is raising its full-year revenue and EPS guidance for 2026, expecting revenues between $11.78 billion and $11.9 billion (6.8% to 7.8% growth) and adjusted EPS in the range of $10.63 to $10.83. Operating margin is expected to expand. The company plans to open a state-of-the-art lab in Southeast Michigan next year as part of its joint venture with Corewell Health. Quest anticipates remaining a leading source of diagnostic innovation for managing diseases like Alzheimer's. The Invigorate program is expected to continue delivering 3% in annual cost savings and productivity improvements. Project Nova, a multiyear initiative to transform order-to-cash processes, is on track for its first wave of solutions in fall 2027. Organic utilization and revenue per requisition (excluding key partnerships) are expected to remain strong. The company anticipates some negative weather impact in the second half of the year and elevated fuel costs. Project Nova expenses are expected to be higher in the second half of the year. The company maintains an assumption of a 30 basis point impact to revenues from ACA disenrollments, though not observed in Q1. Quest is hopeful the RESULTS Act will pass to keep PAMA rates as is for 2027, or that broader data submission will lead to a price increase. The company will continue to pursue other partnerships in consumer health and wellness, and 60-70% of AI/automation efforts will remain focused on laboratory operations. | Diagnostics | The convergence of consumer health, wellness, wearables, and artificial intelligence is emerging as a profound trend that will reshape healthcare. This includes the 'physical of the future,' where wearable data and lab results are analyzed by AI before a doctor's visit, informing a more focused discussion between patient and physician. The linkage between biometrics (from wearables) and biomarkers (from lab tests), enhanced by AI, is highlighted as incredibly important for proactive health management and is expected to increase longitudinal testing by consumers. | Our strong first quarter performance reflects a focused business, delivering innovative solutions. We grew revenues over 9%, almost entirely from organic revenue growth. We grew adjusted diluted earnings per share by approximately 13%, supported by productivity gains from our deployment of automation and AI. We are raising our revenue and EPS guidance for the year. Our pipeline of potential Co-Lab collaborations as well as potential outreach and independent acquisitions remain strong. Our Alzheimer's book of testing more than doubled year-over-year. We expect to continue to deliver 3% in annual cost savings and productivity improvements. We boosted productivity by 40% in the first quarter among customer service agents that used AI. Patients have engaged Quest AI Companion approximately 350,000 times. The M&A funnel is good. The margin on these deals is on par, if not slightly better than our overall enterprise average. | The business mix from these 2 collaborations [Fresenius and Corewell] includes a greater proportion of routine tests... total revenue per requisition, which was down 1.3%. Cash from operations was lower than a year ago due to the timing of operating receipts and disbursements and higher bonus payments. We are expecting in the second half of the year this year that we're going to have some negative weather. Fuel costs will continue to be elevated somewhere at the $4 per gallon and above, impacting the next 3 quarters. We have built in, in our guide still the expectation that we do see a 30 basis point impact to revenues as a result of ACA disenrollments. There's a lot to get done before the end of this year [for RESULTS Act], especially with summer vacations and elections coming up. Routine and wellness tests that are critical to preventative health and wellness... those test categories were actually down. |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| DGX_ae4871f6 | early next year | 2027-01-01 | 2027-03-31 | Launch of a state-of-the-art lab in Southeast Michigan as part of the joint venture with Corewell Health. | This joint venture is a significant growth driver for Quest's hospital channel, contributing to volume growth and expanding collaborative lab solutions. | Ticker | 2026-04-21 | earnings_transcript |